373110.KQ
Xcell Therapeutics, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 1,120.00
−2.44%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.4B | 1.9B | 1.9B | 1.1B | 1.0B |
| Cost of Revenue | 6.5B | 3.9B | 3.3B | 3.0B | 2.8B |
| Gross Profit | (2.1B) | (2.0B) | (1.4B) | (1.9B) | (1.7B) |
| Operating Expenses | |||||
| R&D Expense | 2.5B | 2.3B | 2.7B | 2.8B | 2.6B |
| SG&A Expense | 3.8B | 2.2B | 2.0B | 1.5B | 3.2B |
| General & Admin Expense | 1.1B | 1.3B | 899.7M | 570.6M | 535.9M |
| Selling & Marketing Expense | 575.1M | 907.1M | 1.1B | 932.9M | 692.9M |
| Other Expenses | 4.8B | 4.4B | 3.2B | 2.6B | 740.3M |
| Total Operating Expenses | 9.2B | 8.9B | 7.9B | 6.8B | 6.6B |
| Cost and Expenses | 18.3B | 12.8B | 11.3B | 9.8B | 9.3B |
| Operating Income (EBIT) | (13.9B) | (10.9B) | (9.3B) | (8.7B) | (8.3B) |
| Non-Operating | |||||
| Interest Income | 170.4M | 143.0M | 201.3M | 50.8M | 114.0M |
| Interest Expense | 483.7M | 317.1M | 4.4M | 3.1M | 2.9M |
| Net Interest Income | (313.2M) | (174.1M) | 196.9M | 47.7M | 111.1M |
| Other Non-Op Income/Expense | 2.9B | (71.9M) | (213.3M) | (574.7M) | (43.4M) |
| Non-Operating Income (excl Interest) | 174.6M | — | 208.9M | 571.5M | 40.5M |
| EBT (Pre-Tax Income) | (11.1B) | (10.9B) | (9.5B) | (9.3B) | (8.3B) |
| Income Tax Expense | (65.5M) | — | — | — | (17.0M) |
| Bottom Line | |||||
| Net Income | (11.1B) | (10.9B) | (9.5B) | (9.3B) | (8.3B) |
| Earnings from Cont. Ops | (11.1B) | (10.9B) | (9.5B) | (9.3B) | (8.3B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.1B) | (10.9B) | (9.5B) | (9.3B) | (8.3B) |
| Per Share | |||||
| Basic EPS | (₩734) | (₩938) | (₩874) | (₩1,049) | (₩953) |
| Diluted EPS | (₩734) | (₩938) | (₩874) | (₩1,049) | (₩953) |
| Revenue Per Share | ₩252 | ₩167 | ₩177 | ₩127 | ₩117 |
| Shares | |||||
| Basic Shares Outstanding | 17.3M | 11.6M | 10.9M | 8.8M | 8.8M |
| Diluted Shares Outstanding | 17.3M | 11.6M | 10.9M | 8.8M | 8.8M |
| Profitability Metrics | |||||
| EBITDA | (9.7B) | (9.2B) | (7.9B) | (7.7B) | (6.8B) |
| D&A | 1.6B | 1.7B | 1.7B | 1.6B | 1.5B |
| EBIT | (11.0B) | (10.9B) | (9.5B) | (9.3B) | (8.3B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026